Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.52 |
| ▸ | RORA | P35398 | 11/20 | 0.49 |
| ▸ | RORC | P51449 | 11/20 | 0.49 |
| ▸ | RORB | Q92753 | 11/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1809852 | 0.81 | PGR (0.53) | PGRRORARORCRORBNR1H3 | |
| SCHEMBL1813839 | 0.79 | PGR (0.54) | PGRRORARORCRORBNR1H3 | |
| SCHEMBL14141595 | 0.79 | PGR (0.78) | PGRRORARORCRORBNR1H3 | |
| SCHEMBL1812622 | 0.79 | PGR (0.54) | PGRRORARORCRORBNR1H3 | |
| SCHEMBL1812093 | 0.78 | PGR (0.46) | PGRRORARORCRORBNR1H3 | |
| SCHEMBL1811056 | 0.73 | PGR (0.47) | PGRRORARORCRORBNR1H3 | |
| SCHEMBL1811641 | 0.73 | APP (0.49) | PGRNR1H3NR1H2 | |
| SCHEMBL1808695 | 0.72 | PGR (0.44) | PGRRORARORCRORBNR1H3 | |
| SCHEMBL1810597 | 0.71 | PGR (0.45) | PGRRORARORCRORBNR1H3 | |
| SCHEMBL1809861 | 0.71 | PGR (0.45) | PGRRORARORCRORBNR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4682192-B2 | — | — | 2011-05-11 | — | — | JP | claimed |
| EP-2114897-A2 | BENZIMIDAZOLONE DERIVATIVES | Pfizer Products Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| EP-1756096-B1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-08-12 | — | — | EP | claimed |
| WO-2008032164-A2 | BENZIMIDAZOLONE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | claimed |
| EP-1756096-A1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | claimed |
| US-7173048-B2 | Indolyl derivatives as liver-X-receptor (LXR) modulators | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | claimed |
| WO-2005105791-A1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | WO | claimed |
| US-20050245515-A1 | Indolyl derivatives as liver-X-receptor (LXR) modulators | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-03 | — | — | US | claimed |
| EP-1756096-B1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-08-12 | — | — | EP | disclosed |
| US-7485652-B2 | Indolyl derivatives as liver-X-receptor (LXR) modulators | HOFFMANN-LA ROCHE INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20070099916-A1 | Indolyl derivatives as liver-x-receptor (LXR) modulators | DEHMLOW HENRIETTA | 2007-05-03 | — | — | US | disclosed |
| EP-1756096-A1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-7173048-B2 | Indolyl derivatives as liver-X-receptor (LXR) modulators | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2005105791-A1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245515-A1 | Indolyl derivatives as liver-X-receptor (LXR) modulators | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245515-A1 | Indolyl derivatives as liver-X-receptor (LXR) modulators | INSR, NR1H2, NR1H3 | PGR 210/4885RORA 64/4885RORC 178/4885 |
| US-20070099916-A1 | Indolyl derivatives as liver-x-receptor (LXR) modulators | INSR, NR1H2, NR1H3 | PGR 210/4885RORA 64/4885RORC 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.